Baidu
map

FDA批准聚多卡醇泡沫硬化剂治疗大隐静脉曲张

2013-11-29 晓静 编译 医学论坛网

2013年11月26日,美国食品与药物管理局(FDA)批准聚多卡醇泡沫硬化剂治疗静脉功能不全和大隐静脉曲张。研究显示,聚多卡醇泡沫硬化剂可对大多数浅表静脉功能不全、可视的静脉曲张和潜在静脉功能不全患者的症状有临床意义的改善作用。 原文出处:FDA OKs New Minimally Invasive Treatment for Varicose Veins.November 26,

2013年11月26日,美国食品与药物管理局(FDA)批准聚多卡醇泡沫硬化剂治疗静脉功能不全和大隐静脉曲张。研究显示,聚多卡醇泡沫硬化剂可对大多数浅表静脉功能不全、可视的静脉曲张和潜在静脉功能不全患者的症状有临床意义的改善作用。


原文出处:

FDA OKs New Minimally Invasive Treatment for Varicose Veins.November 26, 2013


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2006675, encodeId=8a4f20066e508, content=<a href='/topic/show?id=082a44042ca' target=_blank style='color:#2F92EE;'>#大隐静脉曲张#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44042, encryptionId=082a44042ca, topicName=大隐静脉曲张)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77b32500129, createdName=12498aa2m62(暂无昵称), createdTime=Sun Apr 20 12:07:00 CST 2014, time=2014-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1662710, encodeId=09581662e1034, content=<a href='/topic/show?id=a3d644038c3' target=_blank style='color:#2F92EE;'>#大隐静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44038, encryptionId=a3d644038c3, topicName=大隐静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=98ce25462322, createdName=ms306040998833292, createdTime=Fri Jul 11 01:07:00 CST 2014, time=2014-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839267, encodeId=a1ed183926e3d, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Wed May 14 06:07:00 CST 2014, time=2014-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697189, encodeId=5b44169e1895b, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Tue Aug 05 00:07:00 CST 2014, time=2014-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801370, encodeId=0d4618013e06e, content=<a href='/topic/show?id=a8b7e3586b5' target=_blank style='color:#2F92EE;'>#硬化剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73586, encryptionId=a8b7e3586b5, topicName=硬化剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6ac207, createdName=xlwang2691, createdTime=Sat Feb 15 14:07:00 CST 2014, time=2014-02-15, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2006675, encodeId=8a4f20066e508, content=<a href='/topic/show?id=082a44042ca' target=_blank style='color:#2F92EE;'>#大隐静脉曲张#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44042, encryptionId=082a44042ca, topicName=大隐静脉曲张)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77b32500129, createdName=12498aa2m62(暂无昵称), createdTime=Sun Apr 20 12:07:00 CST 2014, time=2014-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1662710, encodeId=09581662e1034, content=<a href='/topic/show?id=a3d644038c3' target=_blank style='color:#2F92EE;'>#大隐静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44038, encryptionId=a3d644038c3, topicName=大隐静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=98ce25462322, createdName=ms306040998833292, createdTime=Fri Jul 11 01:07:00 CST 2014, time=2014-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839267, encodeId=a1ed183926e3d, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Wed May 14 06:07:00 CST 2014, time=2014-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697189, encodeId=5b44169e1895b, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Tue Aug 05 00:07:00 CST 2014, time=2014-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801370, encodeId=0d4618013e06e, content=<a href='/topic/show?id=a8b7e3586b5' target=_blank style='color:#2F92EE;'>#硬化剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73586, encryptionId=a8b7e3586b5, topicName=硬化剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6ac207, createdName=xlwang2691, createdTime=Sat Feb 15 14:07:00 CST 2014, time=2014-02-15, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2006675, encodeId=8a4f20066e508, content=<a href='/topic/show?id=082a44042ca' target=_blank style='color:#2F92EE;'>#大隐静脉曲张#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44042, encryptionId=082a44042ca, topicName=大隐静脉曲张)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77b32500129, createdName=12498aa2m62(暂无昵称), createdTime=Sun Apr 20 12:07:00 CST 2014, time=2014-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1662710, encodeId=09581662e1034, content=<a href='/topic/show?id=a3d644038c3' target=_blank style='color:#2F92EE;'>#大隐静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44038, encryptionId=a3d644038c3, topicName=大隐静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=98ce25462322, createdName=ms306040998833292, createdTime=Fri Jul 11 01:07:00 CST 2014, time=2014-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839267, encodeId=a1ed183926e3d, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Wed May 14 06:07:00 CST 2014, time=2014-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697189, encodeId=5b44169e1895b, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Tue Aug 05 00:07:00 CST 2014, time=2014-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801370, encodeId=0d4618013e06e, content=<a href='/topic/show?id=a8b7e3586b5' target=_blank style='color:#2F92EE;'>#硬化剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73586, encryptionId=a8b7e3586b5, topicName=硬化剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6ac207, createdName=xlwang2691, createdTime=Sat Feb 15 14:07:00 CST 2014, time=2014-02-15, status=1, ipAttribution=)]
    2014-05-14 bugit
  4. [GetPortalCommentsPageByObjectIdResponse(id=2006675, encodeId=8a4f20066e508, content=<a href='/topic/show?id=082a44042ca' target=_blank style='color:#2F92EE;'>#大隐静脉曲张#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44042, encryptionId=082a44042ca, topicName=大隐静脉曲张)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77b32500129, createdName=12498aa2m62(暂无昵称), createdTime=Sun Apr 20 12:07:00 CST 2014, time=2014-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1662710, encodeId=09581662e1034, content=<a href='/topic/show?id=a3d644038c3' target=_blank style='color:#2F92EE;'>#大隐静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44038, encryptionId=a3d644038c3, topicName=大隐静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=98ce25462322, createdName=ms306040998833292, createdTime=Fri Jul 11 01:07:00 CST 2014, time=2014-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839267, encodeId=a1ed183926e3d, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Wed May 14 06:07:00 CST 2014, time=2014-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697189, encodeId=5b44169e1895b, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Tue Aug 05 00:07:00 CST 2014, time=2014-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801370, encodeId=0d4618013e06e, content=<a href='/topic/show?id=a8b7e3586b5' target=_blank style='color:#2F92EE;'>#硬化剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73586, encryptionId=a8b7e3586b5, topicName=硬化剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6ac207, createdName=xlwang2691, createdTime=Sat Feb 15 14:07:00 CST 2014, time=2014-02-15, status=1, ipAttribution=)]
    2014-08-05 fusion
  5. [GetPortalCommentsPageByObjectIdResponse(id=2006675, encodeId=8a4f20066e508, content=<a href='/topic/show?id=082a44042ca' target=_blank style='color:#2F92EE;'>#大隐静脉曲张#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44042, encryptionId=082a44042ca, topicName=大隐静脉曲张)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77b32500129, createdName=12498aa2m62(暂无昵称), createdTime=Sun Apr 20 12:07:00 CST 2014, time=2014-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1662710, encodeId=09581662e1034, content=<a href='/topic/show?id=a3d644038c3' target=_blank style='color:#2F92EE;'>#大隐静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44038, encryptionId=a3d644038c3, topicName=大隐静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=98ce25462322, createdName=ms306040998833292, createdTime=Fri Jul 11 01:07:00 CST 2014, time=2014-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839267, encodeId=a1ed183926e3d, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Wed May 14 06:07:00 CST 2014, time=2014-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697189, encodeId=5b44169e1895b, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Tue Aug 05 00:07:00 CST 2014, time=2014-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801370, encodeId=0d4618013e06e, content=<a href='/topic/show?id=a8b7e3586b5' target=_blank style='color:#2F92EE;'>#硬化剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73586, encryptionId=a8b7e3586b5, topicName=硬化剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6ac207, createdName=xlwang2691, createdTime=Sat Feb 15 14:07:00 CST 2014, time=2014-02-15, status=1, ipAttribution=)]
Baidu
map
Baidu
map
Baidu
map